Resources/
Phil Blog

Editor’s Note: The drug channel has evolved and will continue to change as business models shift, consumers prioritize new means of accessing healthcare, and policy changes are implemented. Achieving long-term, sustainable growth is perhaps more difficult than ever for life sciences manufacturers marketing innovative, branded therapies. Recent research by leading consulting firm Accenture provides a key insight that all manufacturers would be wise to consider - the common thread amongst all high performing brands is a continued investment in commercial innovation

This week, we had the opportunity to interview Angie Stigliano, Operational Lead Pharmacist, for our Employee Spotlight series. We hope you enjoy getting to know a little bit about her, and her experience at Phil. Tell me a little bit about yourself and what brought you to Phil I have been a pharmacist since 2016

Editor’s Note: The role of compelling scientific evidence will continue to be a critical component of the life sciences commercialization playbook to ensure HCP adoption. As the authors of the McGill study explained in this article point out, commercial teams should not underestimate the value of creating a robust, diverse body of scientific evidence when seeking to unlock HCP adoption. However, while clinical efficacy is a necessary condition for prescriber adoption and brand success, it’s no longer sufficient to guarantee it

The Healthcare system is notoriously complicated and opaque, making it arduous for patients to navigate successfully. That’s why there’s been a legislative push to increase transparency across through policies such as the No Surprises Act and Hospital Pricing Transparency rule. Getting access to prescribed therapies to treat complex medical conditions can be especially difficult and stressful for patients

Editor’s Note: It should come as no surprise that demand in the life sciences industry for health technologies that can accelerate the process of bringing innovative therapies to market and successfully commercializing them is high. However, having been previously burned by technology that failed to deliver on their complex needs in the past, biopharma has lagged behind other industries in its digital transformation. In fact, even today, many commercialization plans still rely on antiquated, telephonic patient engagement strategies and operate with limited visibility into the prescription journey